Jayempi: Uses, Dosage & Side Effects
Azathioprine oral suspension (10 mg/ml) – an immunosuppressant used to prevent organ transplant rejection and treat severe autoimmune diseases
Jayempi is a branded oral suspension formulation of azathioprine (10 mg/ml), a well-established immunosuppressant medication that has been used in clinical practice for over 50 years. It is prescribed to prevent organ rejection after kidney, liver, or heart transplantation, and to treat a range of severe autoimmune and inflammatory conditions including rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and autoimmune hepatitis. The liquid formulation is particularly beneficial for patients who have difficulty swallowing tablets, including children, elderly patients, and those requiring precise dose adjustments. Azathioprine works by suppressing the immune system through inhibition of purine synthesis, reducing the activity of immune cells that cause inflammation and tissue damage.
Quick Facts: Jayempi
Key Takeaways
- Jayempi is an oral suspension of azathioprine (10 mg/ml), providing a convenient liquid alternative for patients unable to swallow tablets, including children and elderly patients who require precise dose titration.
- It is used to prevent organ transplant rejection and to treat severe autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), and autoimmune hepatitis.
- TPMT and NUDT15 enzyme testing before starting treatment is strongly recommended, as patients with reduced enzyme activity face a significantly higher risk of severe bone marrow suppression at standard doses.
- Regular blood monitoring (complete blood count and liver function tests) is essential throughout treatment – weekly for the first 8 weeks, then at least every 1–3 months – to detect potentially dangerous changes in blood cell counts early.
- The combination of azathioprine with allopurinol or febuxostat is potentially life-threatening without major dose reduction; patients must inform all healthcare providers about their azathioprine treatment before starting any new medication.
What Is Jayempi and What Is It Used For?
Jayempi contains the active substance azathioprine, one of the most widely used and extensively studied immunosuppressant medications in the history of modern medicine. Azathioprine was first synthesized in 1957 by George Hitchings and Gertrude Elion at Burroughs Wellcome (research that would later earn them the Nobel Prize in Physiology or Medicine in 1988) as part of their groundbreaking work on rational drug design targeting nucleic acid metabolism. Since its introduction into clinical practice in the early 1960s, azathioprine has been a cornerstone of immunosuppressive therapy worldwide.
Azathioprine is a prodrug – meaning it is not pharmacologically active in its administered form but is rapidly converted in the body to its active metabolite, 6-mercaptopurine (6-MP). This conversion occurs through a non-enzymatic reaction with glutathione, mediated in part by glutathione S-transferase. Once formed, 6-MP undergoes further intracellular metabolism through three competing enzymatic pathways. The enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT) converts 6-MP into the pharmacologically active 6-thioguanine nucleotides (6-TGN), which are incorporated into DNA and RNA of dividing cells, particularly lymphocytes. This incorporation disrupts normal nucleic acid synthesis and function, triggering cell death (apoptosis) in rapidly proliferating immune cells. Simultaneously, 6-MP is inactivated by xanthine oxidase (XO) and thiopurine S-methyltransferase (TPMT). The balance between these activating and inactivating pathways determines both the therapeutic effect and the toxicity profile of azathioprine in each individual patient.
The net immunosuppressive effect of azathioprine involves suppression of both the adaptive and innate immune responses. It reduces the number and function of T lymphocytes (both helper and cytotoxic T cells), decreases antibody production by B lymphocytes, reduces the number of circulating natural killer (NK) cells, and inhibits the proliferation of monocytes and macrophages. These effects develop gradually over weeks to months, which explains why the full therapeutic benefit of azathioprine is typically not observed until 6 to 12 weeks after starting treatment. This gradual onset is an important clinical consideration that patients should understand when beginning therapy.
Jayempi is specifically formulated as an oral suspension at a concentration of 10 mg/ml. This liquid formulation was developed to address a significant unmet medical need: many patients who require azathioprine – including young children, elderly patients with swallowing difficulties, patients receiving nasogastric tube feeding, and those requiring very precise dose adjustments – cannot easily take conventional tablet formulations. Prior to the availability of licensed oral suspensions, healthcare professionals often had to prepare unlicensed ("extemporaneous") liquid preparations from crushed tablets, which carried risks of dosing inaccuracy, microbiological contamination, and inconsistent bioavailability. Jayempi provides a standardized, licensed, and quality-controlled alternative with a known and consistent pharmacokinetic profile.
Approved Indications
Jayempi is approved for use in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving kidney, liver, or heart allografts. In the transplant setting, azathioprine is typically used as part of a multi-drug immunosuppressive regimen alongside a calcineurin inhibitor (such as ciclosporin or tacrolimus) and corticosteroids. This combination approach allows lower doses of each individual agent to be used, reducing the overall burden of side effects while maintaining effective immunosuppression.
Beyond transplantation, Jayempi is indicated for the treatment of moderate to severe autoimmune and inflammatory conditions where the immune system is inappropriately activated and causes tissue damage. These conditions include:
- Severe rheumatoid arthritis that has not responded adequately to first-line disease-modifying antirheumatic drugs (DMARDs) such as methotrexate.
- Systemic lupus erythematosus (SLE) for maintenance therapy and as a steroid-sparing agent to reduce the need for long-term high-dose corticosteroids.
- Dermatomyositis and polymyositis as part of the immunosuppressive management of these inflammatory muscle diseases.
- Autoimmune hepatitis as maintenance therapy, often in combination with low-dose prednisolone, to prevent disease relapse.
- Inflammatory bowel disease (IBD) including both Crohn’s disease and ulcerative colitis, for maintaining remission and reducing reliance on corticosteroids.
- Polyarteritis nodosa and other systemic vasculitides.
- Autoimmune hemolytic anemia and chronic refractory idiopathic thrombocytopenic purpura (ITP).
The Jayempi oral suspension provides a critical advantage over tablet formulations for several patient groups. Children, particularly those with inflammatory bowel disease or autoimmune hepatitis, often require weight-based dosing that necessitates doses not easily achievable with available tablet strengths. Elderly patients and those with neurological conditions affecting swallowing can take the liquid safely. The oral suspension also enables gradual dose titration in 0.5 mg increments (0.05 ml), which is important for optimizing the balance between efficacy and side effects.
What Should You Know Before Taking Jayempi?
Contraindications
Jayempi must not be used in patients with known hypersensitivity to azathioprine, 6-mercaptopurine (the active metabolite of azathioprine), or to any of the excipients contained in the formulation. Cross-sensitivity between azathioprine and 6-mercaptopurine is expected due to their structural similarity, and patients who have experienced adverse reactions to one agent should not be given the other.
Azathioprine must not be used during pregnancy unless there are no safer alternatives and the potential benefit to the mother clearly justifies the potential risk to the fetus. It is also contraindicated in patients with severe infections, as the immunosuppressive effects of the drug could lead to overwhelming or fatal infection. Vaccination with live vaccines (such as MMR, varicella, BCG, oral polio, and yellow fever) is contraindicated during azathioprine treatment and for at least 3 months after discontinuation, as the impaired immune response may lead to vaccine-associated infection.
Warnings and Precautions
Before starting azathioprine, TPMT (thiopurine S-methyltransferase) genotyping or phenotyping is strongly recommended. Approximately 10% of the population has intermediate TPMT activity and 0.3% has very low or absent TPMT activity. Patients with reduced TPMT are at dramatically increased risk of severe, potentially fatal myelosuppression (bone marrow failure) at standard doses. NUDT15 testing is also recommended, particularly in patients of East Asian descent, where NUDT15 variants are more prevalent. Dose adjustments based on enzyme status are essential.
The most important clinical concern with azathioprine therapy is myelosuppression – the suppression of bone marrow function leading to reduced production of blood cells. This can manifest as leukopenia (low white blood cell count, increasing infection risk), thrombocytopenia (low platelet count, increasing bleeding risk), anemia (low red blood cell count), or pancytopenia (reduction of all blood cell types). Myelosuppression can occur at any time during treatment but is most common in the first weeks and months. It may be sudden and unpredictable, even in patients with normal TPMT activity.
Regular hematological monitoring is mandatory throughout the duration of azathioprine therapy. The following monitoring schedule is recommended:
- First 8 weeks of treatment: Complete blood count (CBC) including differential white cell count and platelet count should be performed weekly.
- After 8 weeks: Blood counts should be performed at least every 1 to 3 months, or more frequently if doses are changed, if high doses are used, if the patient has renal or hepatic impairment, or if signs of bone marrow toxicity develop.
- Liver function tests should also be monitored regularly, as azathioprine can cause hepatotoxicity, including cholestatic jaundice, hepatic veno-occlusive disease, and peliosis hepatis.
Long-term immunosuppression with azathioprine increases the risk of developing certain cancers, including non-melanoma skin cancer and lymphoma (particularly hepatosplenic T-cell lymphoma, which has been reported primarily in young patients with IBD receiving azathioprine in combination with anti-TNF agents). Patients should minimize UV exposure by using sunscreen (SPF 50+), wearing protective clothing, and avoiding sunbeds. Regular skin examinations by a dermatologist are recommended for long-term users.
Pregnancy and Breastfeeding
Azathioprine crosses the placenta and has been detected in fetal blood and amniotic fluid. Animal studies have shown teratogenic effects (birth defects), and human data report an increased risk of premature birth, low birth weight, and transient neonatal immunosuppression and bone marrow suppression. However, these risks must be balanced against the consequences of uncontrolled disease in the mother. In some conditions, such as organ transplantation, autoimmune hepatitis, or severe SLE, discontinuation of azathioprine during pregnancy may pose a greater risk to both mother and fetus than continuing therapy.
Current international guidelines from the British Society for Rheumatology (BSR), the European League Against Rheumatism (EULAR), and the American College of Rheumatology (ACR) recognize azathioprine as one of the few immunosuppressants that may be continued during pregnancy when clinically necessary, provided the dose is kept as low as possible and the patient is closely monitored. The decision should always be made on an individual basis by a specialist experienced in managing immunosuppressed pregnant patients.
Both men and women of reproductive potential should use effective contraception during azathioprine treatment and for at least 3 months after stopping the drug. Men taking azathioprine should be counseled that the drug may affect sperm quality, although current evidence does not demonstrate a significant increase in birth defects in children fathered by men taking azathioprine.
6-Mercaptopurine, the active metabolite of azathioprine, has been detected in breast milk. Breastfeeding during azathioprine treatment is generally not recommended, although some specialist guidelines suggest it may be considered on a case-by-case basis when the dose is low and the infant is monitored.
Driving and Operating Machinery
No specific studies have been performed on the effect of azathioprine on the ability to drive or use machines. Based on its known pharmacological properties, azathioprine is not expected to impair these abilities directly. However, patients should be aware that the condition being treated, as well as potential side effects such as nausea, fatigue, or dizziness, could affect driving ability.
How Does Jayempi Interact with Other Drugs?
Azathioprine has a number of clinically significant drug interactions that require careful management. Unlike monoclonal antibodies that have minimal interaction potential, azathioprine is extensively metabolized by several enzyme systems, and interference with these pathways can dramatically alter drug levels and toxicity. Understanding these interactions is critical for the safe use of Jayempi.
| Interacting Drug | Mechanism | Clinical Effect | Severity |
|---|---|---|---|
| Allopurinol | Inhibits xanthine oxidase, blocking azathioprine/6-MP breakdown | Up to 4-fold increase in active metabolites; severe myelosuppression | Major – dose must be reduced to 25% |
| Febuxostat | Inhibits xanthine oxidase (same mechanism as allopurinol) | Severe myelosuppression | Major – co-administration not recommended |
| Aminosalicylates (mesalazine, olsalazine, sulfasalazine) | Inhibit TPMT enzyme activity | Increased 6-TGN levels; enhanced myelosuppression | Moderate – monitor blood counts closely |
| Warfarin and other coumarins | Azathioprine may reduce anticoagulant effect | Decreased INR; potential for inadequate anticoagulation | Moderate – monitor INR frequently |
| ACE inhibitors (enalapril, ramipril) | Additive leukopenic effect | Increased risk of leukopenia and anemia | Moderate – monitor blood counts |
| Live vaccines | Impaired immune response to vaccination | Risk of vaccine-derived infection; reduced vaccine efficacy | Contraindicated |
| Ribavirin | Inhibits inosine monophosphate dehydrogenase | Accumulation of 6-methylthioinosine monophosphate; increased myelotoxicity | Major – avoid combination if possible |
| Neuromuscular blockers (tubocurarine, succinylcholine) | Azathioprine inhibits cholinesterase | Prolonged neuromuscular blockade during anesthesia | Moderate – inform anesthesiologist |
Major Interactions
The interaction between azathioprine and allopurinol is one of the most clinically dangerous drug interactions in all of medicine. Allopurinol is commonly prescribed for gout and hyperuricemia, and it works by inhibiting xanthine oxidase (XO), the same enzyme that is responsible for the metabolic inactivation of a significant proportion of azathioprine and its metabolite 6-mercaptopurine. When xanthine oxidase is inhibited by allopurinol, the concentration of active and toxic thiopurine metabolites can increase by three- to four-fold, leading to severe and potentially fatal bone marrow suppression. If co-administration is absolutely unavoidable, the azathioprine dose must be reduced to approximately 25% (one quarter) of the standard dose, and blood counts must be monitored very closely. Febuxostat, another xanthine oxidase inhibitor, carries the same risk and its concurrent use with azathioprine is generally not recommended by the EMA.
Minor Interactions
Azathioprine may reduce the anticoagulant effect of warfarin and other coumarin-type anticoagulants. The mechanism is not fully understood but may relate to increased hepatic metabolism of vitamin K-dependent clotting factors. Patients receiving both azathioprine and warfarin should have their INR monitored more frequently, particularly when azathioprine is started, stopped, or the dose is changed. Inactivated vaccines may be administered during azathioprine treatment, but the immune response may be reduced. Patients should be advised that vaccination may be less effective and that antibody titers should be checked after vaccination where possible.
Always carry a patient alert card or medical identification indicating that you are taking an immunosuppressant. Inform any new doctor, dentist, pharmacist, or healthcare professional about your azathioprine treatment before accepting any new medication, surgical procedure, or vaccination. This is especially important before starting gout medications, antibiotics, or antiviral drugs.
What Is the Correct Dosage of Jayempi?
Jayempi should always be used exactly as prescribed by your doctor. The oral suspension (10 mg/ml) should be measured using the graduated oral syringe provided with the product to ensure accurate dosing. Shake the bottle well before each use. The dose is highly individualized and depends on the indication being treated, the patient’s body weight, their TPMT/NUDT15 enzyme status, concomitant medications, response to therapy, and hematological tolerance.
Adults
| Indication | Starting Dose | Maintenance Dose | Notes |
|---|---|---|---|
| Transplant prophylaxis | Up to 5 mg/kg/day | 1–3 mg/kg/day | Usually combined with ciclosporin/tacrolimus and corticosteroids |
| Rheumatoid arthritis | 1 mg/kg/day | 1–3 mg/kg/day | Increase gradually over 6–8 weeks; therapeutic effect may take 12 weeks |
| SLE / Other autoimmune | 1–3 mg/kg/day | Lowest effective dose | Adjust based on clinical response and blood counts |
| Autoimmune hepatitis | 1–1.5 mg/kg/day | 1–2 mg/kg/day | Combined with prednisolone; often long-term maintenance |
| IBD (Crohn’s/UC) | 1.5–2.5 mg/kg/day | 2–2.5 mg/kg/day | Full effect may take 3–6 months; steroid-sparing role |
When starting azathioprine for autoimmune indications, most guidelines recommend beginning at a lower dose (1 mg/kg/day) and gradually increasing over several weeks while monitoring blood counts. This "start low, go slow" approach helps identify patients who are unexpectedly sensitive to the drug before they are exposed to full therapeutic doses. The therapeutic response is typically gradual, and patients should be counseled that they may not notice improvement for 6 to 12 weeks. It is important not to discontinue the medication prematurely due to perceived lack of efficacy.
Children
Jayempi is approved for use in children of all ages. The dosing principles are the same as for adults, with doses calculated on a per-kilogram body weight basis. The oral suspension formulation is particularly advantageous for pediatric patients, as it allows precise weight-based dosing that would be difficult to achieve with tablets alone. In pediatric transplant patients, the starting dose may be up to 5 mg/kg/day, reduced to a maintenance dose of 1–3 mg/kg/day. For autoimmune conditions in children, the typical dose range is 1–3 mg/kg/day. All pediatric patients should have TPMT and NUDT15 genotyping before starting treatment, and blood monitoring should follow the same schedule as for adults.
Elderly Patients
There is limited experience with azathioprine in elderly patients. It is recommended to start at the lower end of the dose range and to monitor hematological parameters more frequently, as elderly patients may have reduced bone marrow reserve and impaired renal function, both of which can increase the risk of myelosuppression. Renal function should be assessed before starting treatment, and dose adjustments should be considered in patients with significant renal impairment.
Dose Adjustments for TPMT/NUDT15 Status
Normal TPMT/NUDT15 Activity
Standard dosing as per indication. Regular monitoring according to standard schedule.
Intermediate TPMT or NUDT15 Activity (Heterozygous)
Start at a reduced dose (typically 50% of standard). Increase cautiously based on hematological response. Monitor blood counts more frequently (at least weekly for the first 2–3 months).
Low/Absent TPMT or NUDT15 Activity (Homozygous Deficient)
Azathioprine should generally be avoided. If absolutely necessary, use a drastically reduced dose (10% of standard or less) with very close hematological monitoring. Consider alternative immunosuppressants.
Missed Dose
If you miss a dose of Jayempi, take it as soon as you remember on the same day. If it is already time for your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one. If you frequently forget doses, consider using a daily alarm or medication reminder app, as consistent dosing is important for maintaining stable immunosuppression and preventing disease flares or transplant rejection.
Overdose
Symptoms of azathioprine overdose may not be immediately apparent but can include unexplained infection, sore throat, bruising, or bleeding – signs that typically develop 9 to 14 days after the overdose as bone marrow suppression becomes clinically manifest. Other symptoms may include nausea, vomiting, diarrhea, and liver function abnormalities. There is no specific antidote for azathioprine. Treatment is supportive, with close monitoring of blood counts and liver function. Azathioprine is partially dialyzable, and hemodialysis may be considered in severe cases to accelerate removal of the drug and its metabolites. If overdose is suspected, contact your doctor or poison control center immediately.
What Are the Side Effects of Jayempi?
Like all immunosuppressant medications, Jayempi can cause side effects, although not everyone experiences them. The most clinically important adverse effects relate to bone marrow suppression and infection, which are direct consequences of the drug’s mechanism of action. The frequency and severity of side effects depend on the dose used, the duration of treatment, the patient’s TPMT/NUDT15 enzyme status, concomitant medications, and individual susceptibility. Regular monitoring allows most serious side effects to be detected early and managed appropriately.
Very Common
- Bone marrow depression (leukopenia, thrombocytopenia)
- Increased susceptibility to infections (viral, bacterial, fungal)
- Nausea
Common
- Anemia
- Loss of appetite (anorexia)
- Vomiting
- Liver function abnormalities (elevated transaminases, bilirubin)
- Cholestatic jaundice
Uncommon
- Pancreatitis (especially in IBD patients and transplant recipients)
- Hypersensitivity reactions (fever, rigors, rash, myalgia, arthralgia, hypotension)
- Diarrhea
- Steatorrhea (fatty stools)
- Alopecia (hair loss)
Rare
- Agranulocytosis (severely low white blood cells)
- Pancytopenia and aplastic anemia
- Megaloblastic anemia
- Hepatic veno-occlusive disease
- Peliosis hepatis
- Stevens-Johnson syndrome and toxic epidermal necrolysis
- Interstitial pneumonitis
Not Known
- Progressive multifocal leukoencephalopathy (PML) – a rare brain infection caused by JC virus
- Hepatosplenic T-cell lymphoma (primarily in young IBD patients on combination therapy)
- Non-melanoma skin cancer with long-term use
- Photosensitivity
Gastrointestinal side effects, particularly nausea, are among the most frequently reported complaints and are a common reason for dose reduction or treatment discontinuation. Nausea can often be managed by taking Jayempi with food or in divided doses (splitting the daily dose into two administrations). If gastrointestinal symptoms are severe and persistent, they may indicate a hypersensitivity reaction to the drug, which typically develops within the first few weeks of treatment and resolves on discontinuation. Rechallenge after a hypersensitivity reaction is not recommended, as symptoms typically recur rapidly and may be more severe.
Pancreatitis occurs in approximately 3–4% of patients with IBD taking azathioprine and typically presents within the first few weeks of treatment with severe abdominal pain, nausea, vomiting, and elevated serum amylase and lipase. It is an idiosyncratic (unpredictable) reaction that is not dose-dependent and resolves upon drug discontinuation. Patients who develop azathioprine-induced pancreatitis should not be rechallenged with the drug.
Contact your doctor immediately or go to the nearest emergency department if you develop: unexplained bruising or bleeding, persistent sore throat or fever, signs of infection, severe abdominal pain, yellowing of skin or eyes, severe skin rash or blistering, or difficulty breathing. These may indicate serious complications requiring urgent medical assessment and possible treatment modification.
How Should You Store Jayempi?
Proper storage of Jayempi is essential to maintain its efficacy, stability, and safety throughout its use. As an oral suspension, Jayempi has different storage requirements compared to tablet formulations, and patients should be carefully instructed on these at the time of dispensing.
The unopened bottle should be stored at temperatures below 25°C (77°F). Do not refrigerate or freeze the suspension, as extreme cold can affect the formulation’s physical characteristics and the uniformity of the suspension. Store the bottle in its original outer carton to protect it from light, as azathioprine can be degraded by prolonged light exposure.
Once the bottle has been opened, the oral suspension remains stable for use for up to 56 days (8 weeks) when stored below 25°C. After this period, any remaining suspension should be discarded, even if the bottle is not empty. Write the date of opening on the bottle label or carton to help track this expiry period. Always shake the bottle well for at least 20 seconds before each use to ensure the suspension is uniformly mixed and the correct concentration of active ingredient is delivered with each dose.
After each use, clean the oral dosing syringe provided with the product by rinsing it with water. Do not use the syringe for any other medication. Keep the bottle cap tightly closed when not in use to prevent contamination. Store Jayempi out of the sight and reach of children. Do not use the suspension if it has changed color, developed an unusual odor, or if particles are visible that do not redisperse after shaking.
Do not dispose of unused medication via household waste or wastewater. As an immunosuppressant with potential mutagenic properties, Jayempi should be returned to your pharmacist for proper disposal through designated pharmaceutical waste channels. This is important to protect the environment and prevent accidental exposure to others.
What Does Jayempi Contain?
The active substance in Jayempi is azathioprine. Each 1 ml of oral suspension contains 10 mg of azathioprine, allowing precise dose measurement using the graduated oral syringe provided. Azathioprine has the molecular formula C9H7N7O2S and a molecular weight of 277.26 daltons. It is a derivative of 6-mercaptopurine (6-MP), with a methyl-nitroimidazole group attached to the sulfur atom of the purine ring. This structural modification improves oral bioavailability compared to 6-MP alone.
The excipients (inactive ingredients) in Jayempi include:
- Sodium benzoate (E211): Used as a preservative to prevent microbial growth in the liquid formulation. Patients with a known sensitivity to benzoate preservatives should inform their doctor.
- Sucralose: A non-nutritive sweetener to improve the taste of the suspension.
- Banana flavoring: Added to improve palatability, particularly important for pediatric patients.
- Citric acid monohydrate: Used as a pH buffer to maintain the stability of the suspension.
- Microcrystalline cellulose and carmellose sodium: Suspending agents that help keep the azathioprine particles uniformly distributed throughout the liquid.
- Xanthan gum: A thickening agent that contributes to the suspension’s viscosity and stability.
- Purified water: The vehicle for the suspension.
Jayempi does not contain gluten, lactose, or ethanol. It is supplied in an amber glass bottle with a child-resistant closure. Each pack includes a graduated oral syringe and a bottle adapter for accurate dose measurement. The banana flavor and sucralose sweetener make the suspension more acceptable to patients, particularly children, compared to the bitter taste of azathioprine in its pure form.
Azathioprine is classified as a cytotoxic agent. While the oral suspension is designed for safe patient use, caregivers and healthcare professionals who handle Jayempi regularly should take precautions to avoid direct skin contact with the suspension. If spillage occurs, clean the area immediately. Pregnant women or those planning pregnancy should avoid handling the suspension. Wash hands thoroughly after administering the medication to a patient.
Frequently Asked Questions About Jayempi
Jayempi contains the same active substance (azathioprine) as tablet formulations such as Imuran and generic azathioprine tablets. The key difference is that Jayempi is an oral suspension (liquid) at a concentration of 10 mg/ml, which makes it easier to swallow for patients who have difficulty with tablets, including children, elderly patients, and those with swallowing disorders. The liquid form also allows for more precise dose adjustments in small increments, which is particularly important for weight-based dosing in children and for gradual dose titration.
Azathioprine has a slow onset of action compared to many other medications. For autoimmune conditions, it typically takes 6 to 12 weeks to achieve a clinically meaningful therapeutic effect, and full benefit may not be apparent for 3 to 6 months. This is because the drug works by gradually suppressing the production and function of immune cells, a process that takes time. In the transplant setting, azathioprine is used from the time of surgery as part of a combination regimen, so its contribution to preventing rejection begins immediately alongside other faster-acting immunosuppressants. It is important not to stop taking the medication early because you feel it is not working.
There is no absolute contraindication to moderate alcohol consumption with azathioprine, but caution is advised. Both azathioprine and alcohol are metabolized by the liver, and azathioprine can cause liver toxicity. Regular or excessive alcohol intake may increase the risk of liver damage. If you choose to drink alcohol, do so in moderation and ensure your liver function tests are being monitored regularly. Discuss your alcohol intake with your doctor so they can monitor you appropriately.
Yes, sun protection is particularly important for patients taking azathioprine. Long-term immunosuppression increases the risk of skin cancer, especially non-melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma). Azathioprine may also increase sensitivity to UV radiation. You should use a broad-spectrum sunscreen with SPF 50 or higher, wear protective clothing (long sleeves, wide-brimmed hat), avoid midday sun exposure, and never use sunbeds or tanning beds. Regular skin checks by a dermatologist are recommended for patients on long-term azathioprine therapy.
Live vaccines (such as MMR, varicella/chickenpox, BCG, oral polio, yellow fever, and live shingles vaccine) are contraindicated while taking azathioprine, as the impaired immune system may not be able to fight the weakened virus, potentially leading to vaccine-derived infection. Inactivated vaccines (such as influenza injection, COVID-19, pneumococcal, and hepatitis B) can be given, but the immune response may be reduced. It is generally recommended to complete all necessary live vaccinations at least 4 weeks before starting azathioprine. If live vaccination is needed, azathioprine should ideally be stopped for at least 3 months beforehand, if clinically safe to do so.
If you develop signs of infection (fever, persistent sore throat, cough, urinary symptoms, skin infection, or any other unusual symptoms), contact your doctor promptly. Because azathioprine suppresses the immune system, infections can progress more rapidly and severely than in people with normal immunity. Your doctor may need to perform blood tests, check your white blood cell count, and possibly prescribe antibiotics or antiviral medication. In some cases, the azathioprine dose may need to be temporarily reduced or held until the infection is controlled. Do not stop taking Jayempi without consulting your doctor, as abrupt discontinuation could lead to disease flare or transplant rejection.
References
- European Medicines Agency (EMA). Jayempi (azathioprine) – Summary of Product Characteristics. Last updated 2025. Available at: EMA Jayempi EPAR.
- Cara CJ, Pena AS, Sans M, et al. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit. 2004;10(11):RA247–256.
- Coenen MJH, de Jong DJ, van Marrewijk CJ, et al. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease. Gastroenterology. 2015;149(4):907–917. doi:10.1053/j.gastro.2015.06.002.
- Yang SK, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014;46(9):1017–1020. doi:10.1038/ng.3060.
- British Society for Rheumatology (BSR). BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding – Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology. 2023;62(4):e89–e104.
- Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106. doi:10.1136/gutjnl-2019-318484.
- Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis. 2024;18(1):1–39.
- Fraiser LH, Kanekal S, Kehrer JP. Cyclophosphamide Toxicity: Characterising and Avoiding the Problem. Drugs. 1991;42(5):781–795. (Comparative immunosuppressant toxicity reference.)
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list, 2023. Azathioprine listed as an essential immunosuppressant.
- British National Formulary (BNF). Azathioprine. National Institute for Health and Care Excellence (NICE). 2026.
About Our Medical Team
All content on iMedic is created and reviewed by qualified medical professionals following international evidence-based guidelines. Our editorial process ensures accuracy, currency, and clinical relevance.
Medical Content Team
Specialists in immunology, transplant medicine, rheumatology, and clinical pharmacology with extensive experience in immunosuppressive therapy management.
Medical Review Board
Independent panel of board-certified physicians who verify all medical claims against current evidence and international guidelines (WHO, EMA, BSR, ACR, ECCO).
Editorial Standards
All content follows the GRADE evidence framework and is based on Level 1A evidence from systematic reviews and randomized controlled trials where available.
Independence
iMedic receives no pharmaceutical company funding or sponsorship. All content is editorially independent, ensuring unbiased medical information for patients and caregivers.